H.C. Wainwright lowers Cocrystal Pharma stock price target on dilution

H.C. Wainwright lowered its price target on Cocrystal Pharma (COCP) to $6.00 from $7.00, maintaining a Buy rating due to anticipated equity dilution, despite positive progress on drug candidates CDI-988 (norovirus) and CC-42344 (influenza). CDI-988 demonstrated "excellent potency" against norovirus, and Cocrystal plans to initiate human challenge studies in 2025, while CC-42344 showed potent antiviral activity against the H5N1 avian influenza strain, exceeding Tamiflu's potency by approximately 1,000 times; a Phase 2a study is planned.

Analysis

H.C. Wainwright has adjusted its price target on Cocrystal Pharma, Inc. (COCP) to $6.00 from $7.00, attributing the reduction to anticipated equity dilution, while notably maintaining a Buy rating; the stock currently trades at $1.55 with a market capitalization of $15.8 million. This outlook reflects a balance between dilution concerns and substantial progress in the company's drug development pipeline. Cocrystal's norovirus candidate, CDI-988, has demonstrated "excellent potency" against the GII.17 protease and is slated for human challenge studies later in 2025, potentially accessing a significant market through stockpiling contracts upon successful proof-of-concept, as there are currently no approved antivirals or vaccines for norovirus. Furthermore, its influenza candidate, CC-42344, has shown potent antiviral activity against the H5N1 avian influenza strain—reportedly approximately 1,000 times more potent than Tamiflu—and is progressing towards a Phase 2a study. InvestingPro data indicates Cocrystal maintains a strong liquidity position with cash reserves exceeding debt obligations, which is crucial for funding these developments targeting significant unmet medical needs.

Key Decisions for Investors

• Investors should consider the maintained Buy rating and the $6.00 price target, which implies significant potential upside from the current $1.55 price, while carefully assessing the impact of anticipated equity dilution on future share value.
• Closely track upcoming clinical milestones, particularly the human challenge study for the norovirus candidate CDI-988 in late 2025 and the advancement of the H5N1 influenza candidate CC-42344 to a Phase 2a study, as these are pivotal for de-risking the pipeline and validating the company's proprietary structure-based platform.
• Evaluate the strategic importance of Cocrystal's strong liquidity position in funding its drug development pipeline, especially for CDI-988 and CC-42344 which address substantial market opportunities with limited current treatments, against the backdrop of its micro-cap status.